The Darnytsia pharmaceutical company in 2020 received a net income of UAH 4.3 billion from the product sales, which is 33.7% more than a year before.

The head of the Board of Directors of Darnytsia Group, Dmytro Shymkiv, reported that Darnytsia contributed about 10% of its income to projects for the digital refurbishment of the company and the development of new medicines. Also, he announced that over the past five years, the company had released more than 45 new medicines, in the development of which Darnytsia Group has invested 35.3 million euros. The total investment of Darnytsia in researching and developing over ten years is around 200 million euros.

Shymkiv noted that the pharmaceutical concern continues the process of large-scale transformation, starting in 2019. After its rebranding, the company set new strategic goals and values and changed its business philosophy. Darnytsia Group strives to build an international pharmaceutical brand, lead the production of complex generics, and digitize its business processes completely. Developing its production and expanding the list of produced medicines, concern management focuses on treating the most common diseases in Ukraine. The company manages to create new medicine through cooperation with other international pharmaceutical companies and its own research. Darnytsia Group spends more than 40% of its total investments annually for the development of new medicines.

In addition to dozens of ready-made medicines on the pharmaceutical market, more than 50 medicines of Darnytsia are at various stages of development. Shymkiv confidently states that they will be registered until 2023. Unlike its competitors in Ukraine, Darnytsia Group specializes in the production of medicines for the prevention and treatment of diseases of the cardiovascular and nervous systems and medicines that eliminate pain symptoms.

Dmytro Shymkiv gladly explained the basis of his optimistic statements regarding the development of the industry. Due to official data, the Ukrainian pharmaceutical market is getting into the global pharma industry market as a fast-growing one. Considering the rate of domestic pharmaceuticals development in terms of percentage, on average, it is 11% per year. This indicator reflects the great perspectives of Ukrainian pharmaceuticals, which is three times higher than the growth rates of the Ukrainian economy.